[Cellular effect of neuroleptics].
D000262:Adenylyl Cyclases; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001693:Biological Transport, Active / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors; D002746:Chlorpromazine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D010868:Pimozide / Q000494:pharmacology; D011955:Receptors, Drug; D012110:Reserpine / Q000494:pharmacology; D012559:Schizophrenia / Q000378:metabolism; D012702:Serotonin Antagonists; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000494:pharmacology*
D002395:Catecholamines; D018492:Dopamine Antagonists; D006634:Histamine H1 Antagonists; D011955:Receptors, Drug; D012702:Serotonin Antagonists; D014149:Tranquilizing Agents; D010868:Pimozide; D012110:Reserpine; D000262:Adenylyl Cyclases; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine
Zum zellulären Wirkungsmechanismus von Neuroleptika